May 14th 2024
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Selinexor-Based Triplet Shows Tolerability With Dose Reductions in RRMM
December 20th 2023In the second article of a 2-part series, Sumit Madan, MD, talked about the manageable toxicity profile with the triplet therapy selinexor (Xpovio), bortezomib, and dexamethasone and how dose reductions led to tolerable outcomes in patients with relapsed/refractory multiple myeloma.
Read More
IsKia: Isa-KRd vs KRd as Pre-Transplant Induction and Post-Transplant Consolidation in NDMM
December 19th 2023Experts on multiple myeloma review recent data updates from the IsKia study looking at Isa-KRd vs KRd as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma.
Watch
PERSEUS: Dara-VRd vs VRd in Patients with NDMM Eligible for Autologous Stem Cell Transplantation
December 19th 2023Following ASH 2023, Jens Hillengass, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the PERSEUS study investigating Dara-VRd in newly diagnosed multiple myeloma.
Watch
Bispecific T-Cell Engagers Raise Questions on Target Selection and Drug Administration
December 18th 2023The approval of talquetamab, a GPRC5D-targeted bispecific T-cell engager, led to discussions in 2 separate Case-Based Roundtable events on therapy sequencing selection, toxicity, and outpatient treatment.
Read More
Trials Shed Light on Transplant and Maintenance in NDMM
December 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the IFM2009, DETERMINATION, and FORTE trials in patients with newly diagnosed multiple myeloma. This is the first of 2 articles based on this event.
Read More
Richter Discusses How Quadruplet Therapy Has Changed Treatment Considerations and Outcomes in NDMM
December 13th 2023During a Targeted Oncology™ Clinical Case Forum event in partnership with the Empire State Hematology & Oncology Society, Joshua Richter, MD, discussed the GRIFFIN trial and issues in treating newly diagnosed multiple myeloma including minimal residual disease, consolidation, maintenance, and transplant.
Read More
Unanswered Questions on Sequencing Talquetamab for RRMM
December 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan L. Kaufman, MD, and participants discussed their impressions of the efficacy and safety of the MonumenTAL-1 trial of talquetamab in patients with heavily pretreated relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
Read More
Daratumumab Plus VRd Betters PFS in Transplant-Eligible, Newly Diagnosed Multiple Myeloma
December 12th 2023Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant and D-VRd consolidation and daratumumab/lenalidomide maintenance significantly prolonged progression-free survival.
Read More
Talquetamab Dose Modifications Maintain Efficacy, Lower AEs for Myeloma
December 12th 2023Dose reductions of the GPRC5D/CD3 bispecific antibody talquetamab effectively improved on-target adverse events while sustaining high response rates for patients with relapsed/refractory multiple myeloma.
Read More
Isatuximab Provides Longer Survival in Early Relpase Multiple Myeloma
December 11th 2023In the second article of a 2-part series, Joshua Richter, MD, discusses how the isatuximab, carfilzomib, and dexamethasone regimen fits into the landscape of treatment for patients with early relapsed multiple myeloma.
Read More
Single and Dual-Target D8 CAR T Cells Show Tolerability, Efficacy in R/R MM
December 10th 2023Investigators in the MCARTY study reported safety and high response rates in a small number of patients with relapsed/refractory multiple myeloma who received chimeric antigen receptor T-cell therapy designed with a new process to target the D8 binder, meant to improve efficacy in targeting BCMA.
Read More
Real-World Analysis Shows Similar Safety, Efficacy With Teclistamab in RRMM
December 9th 2023The retrospective analysis demonstrated comparable outcomes with teclistamab from the phase 2 MajesTEC-1 trial, highlighting the need for close monitoring and supportive care in patients treated for their relapsed or refractory multiple myeloma.
Read More
Understanding Risks and Training Needs for Outpatient Bispecific Usage
December 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Mancini, PharmD, BCOP, FHOPA, discussed the various approved bispecific T-cell engagers and gave guidance for healthcare professionals, patients, and caregivers related to adverse event management. This is the second of 2 articles based on this event.
Read More